ProCE Banner Activity

PARAGON-HF: Sacubitril/Valsartan vs Valsartan in Patients With and Without Diabetes and Heart Failure With Preserved Ejection Fraction

Slideset Download
Conference Coverage
In patients with HFpEF, sacubitril/valsartan attenuated the rate of decline in renal outcomes similarly in patients with and without diabetes compared to valsartan alone.

Released: April 06, 2022

Expiration: April 05, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by an educational grant from

Merck Sharp & Dohme Corp.